For Healthcare Professionals Outside the US
Explore podcasts
View patient management tools
Indication from Summary of Product Characteristics
PIQRAY is indicated in combination with
fulvestrant for the treatment of
postmenopausal women, and men, with hormone
receptor (HR)‐positive, human
epidermal growth factor receptor 2
(HER2)‐negative, locally advanced or
metastatic breast cancer with a PIK3CA
mutation after disease progression following
endocrine therapy as monotherapy.
References:
1. Mosele F,
Stefanovska B,
Lusque A,
et al.
Outcome and molecular landscape of patients with
PIK3CA-mutated metastatic breast cancer.
Ann Oncol. 2020;31(3):377-386.
2. The Cancer Genome
Atlas Network. Comprehensive molecular portraits of
human breast tumours.
Nature. 2012;490(7418):61-70.
3. Chalhoub C,
Baker SJ. PTEN and
the PI3-kinase pathway in cancer.
Annu Rev Pathol. 2009;4:127-150.
4. Piqray®
(alpelisib)
EU Summary of Product Characteristics. Novartis;
2022.
5. André F,
Ciruelos E,
Rubovszky G,
et al. Alpelisib
for PIK3CA-mutated, hormone receptor-positive
advanced breast cancer.
N Engl J Med. 2019;380(20):1929-1940.
This is an international site for PIQRAY®
(alpelisib) and is intended for healthcare professionals
outside the US.